Talniflumate
Completing data — refresh the page later to see the latest
Basic information
- CAS
66898-62-2- Standard SMILES
O=C1OC(OC(=O)c2cccnc2Nc2cccc(C(F)(F)F)c2)c2ccccc21- InChIKey
ANMLJLFWUCQGKZ-UHFFFAOYSA-N- Molecular formula
- C21H13F3N2O4
- Average molar mass
- 414.3 g/mol
- Monoisotopic mass
- 414.08274139
Names & identifiers
- Preferred name
- Talniflumate
- IUPAC
- (3-oxo-1H-2-benzofuran-1-yl) 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate
- English name
- Talniflumate
- Molecular formula
- C21H13F3N2O4
- Molecular weight
- 414.33
Names & synonyms
Talniflumate66898-62-2SomalgenTalniflumatoBA 7602-06TalniflumatumDTXSID3046740Ba-7602-06JFK78S0U9SDTXCID1026740RefChem:8910403-oxo-1,3-dihydro-2-benzofuran-1-yl 2-((3-(trifluoromethyl)phenyl)amino)pyridine-3-carboxylate
Show more names
ba7602-06Talniflumate, >=99%Talniflumate (BA 7602-06)TALNIFLUMATE(INTERMEDIATE)Talniflumate, 10 mM in DMSOphthalidyl2-(3-trifluoromethylanilino)nicotinate2-(α,α,α-Trifluoro-m-toluidino)nicotinic acid phthalidyl esterphthalidyl2-(alpha,alpha,alpha-trifluoro-m-toluidino)nicotinate
LomucinTalniflumatum [INN-Latin]UNII-JFK78S0U9S3-Oxo-1,3-dihydroisobenzofuran-1-yl 2-((3-(trifluoromethyl)phenyl)amino)nicotinateMFCD00866135Phthalidyl 2-(3-trifluoromethylanilino)nicotinateBA7602-06; SomalgenNCGC00167754-01
Database identifiers
- CAS
66898-62-2- PubChem CID
- 48229
- DTXSID
DTXSID3046740- ChEMBL
CHEMBL1081506- ChEBI
CHEBI:91991- UNII
- JFK78S0U9S
- Nikkaji
- J19.136A
Properties
Computed structural propertiesFilling in
- XLogP
- 5.3
- Topological polar surface area
- 77.5 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 9
- Rotatable bonds
- 5
- Heavy atoms
- 30
- Formal charge
- 0
- Complexity
- 644
Experimental & physicochemical properties
LogP4.47
Solubility5
Boiling Point454
Melting Point177
Physicochemical properties
- Melting point
- 165 · 165-167°C
- Boiling point
- 534.6 · 534.6±50.0 °C(Predicted)
- Density
- 1.49 · 1.49±0.1 g/cm3(Predicted)
- storage temp.
- 4 °C · Store at +4°C
- solubility
- Chlorform (Slightly), DMSO (Slightly), Methanol (Slightly)
- pka
- 2.72 · 2.72±0.10(Predicted)
- form
- Solid
- color
- Off-White to Pale Yellow
- λmax
- 287 nm · 287nm(CHCl3)(lit.)
- Merck
- 14 · 14,9044
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Safety data
- wgk
- WGK 3
- rtecs
- QT2999200
- hs_code
- 2933.39.9200
- Toxicity
- LD50 orally in rats: 12000 mg/kg (Los)
- Storage Class
- 11 - Combustible Solids
Chemistry & industry
Pharmacology
Protein BindingNiflumic acid, the active form of Talniflumate, is weak acid that is strongly bound to plasma proteins. Bioavailability was 100% in a study of 12 volunteers. It is a weak acid, strongly bound to plasma proteins.
Pharmacodynamics
Talniflumate is metabolized to its prodrug, niflumic acid, which has several pharmacodynamic effects. Firstly, it blocks synthesis of mucin. Secondly, talniflumate blocks prostaglandin synthesis by cyclooxygenases, which aids in pain and inflammation management.
Mechanism of Action
Talniflumate is a strong and selective inhibitor of core mucin-synthesizing enzyme GCNT3 (core 2 b-1,6 N-acetylglucosaminyltransferase). Talniflumate decreases gene expression of GCNT3 and production of mucins in vivo and in vitro. Talniflumate improves response of pancreatic tumors to gefitinib (chemotherapy drug). Talniflumate is a strong calcium-activated chloride channel (CaCC) blocker.
Biological Half-LifeApproximately 2h in 12 subjects
Metabolism/MetabolitesExtensive liver metabolism.
Absorption, Distribution and Excretion
In 12 subjects after a single oral administration, total plasma clearance of the main metabolite, niflumic acid, averaged 45 ml/min giving a distribution volume of 0.12 l/kg on average.
This drug undergoes extensive first pass effect.
Applications
UsesTalniflumate is a nonaspirin and nonsteroidal anti-inflammatory drug.
UsesAnti-inflammatory; analgesic.
Upstream & downstream products
Upstream raw materials
Suppliers
Loading…
Open inquiries
Loading…
Related reactions
3 records
Compound notes
Loading…